Targeting Virus-Host Interaction: An in Silico Approach to Develop Promising Inhibitors Against COVID-19
The entire human population all over the globe is currently facing appalling conditions due tothe spread of infection from COVID-19 (corona virus disease-2019). In the last few monthsenormous amount of studies have been continuously trying to target several potential drugsites to identify a novel therapeutic target. Spike protein of severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2) is also being targeted by several scientific groups as a noveldrug target. The spike glycoprotein protein is present on the surface of the virion and binds tothe human angiotensin-converting enzyme-2 (hACE2) membrane receptor thereby promotingits fusion to the host cell membrane. The binding and internalization of the virus is a crucialstep in the process of infection and hence any molecule that can inhibit this, certainly holds asignificant therapeutic value. We have identified AP-NP (2-(2-amino-5-(naphthalen-2-yl)pyrimidin-4-yl)phenol) and AP-4-Me-Ph (2-(2-amino-5-(p-tolyl)pyrimidin-4-yl)phenol)from a group of diaryl pyrimidine derivatives which appear to bind at the interface ofhACE2-SARS-CoV-2S complex (human angiotensin converting enzyme 2 and spikeglycoprotein complex) with a low binding energy (<-8 Kcal/mol). In this in-silico study wealso found that AP-NP interacts with S1 domain of C-terminal part of SARS-CoV-2Showever AP-4-Me-Ph was found to interact with S2 domain of SARS-CoV-2S. The resultsuggested that AP-NP and AP-4-Me-Ph have potential to inhibit the interaction betweenspike protein and hACE2 receptor also AP-4-Me-Ph might be prevent internalization of thevirion within the host. Further in vitro and in vivo study will strengthen these drug candidatesagainst the COVID-19..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
chemRxiv.org - (2021) vom: 18. Nov. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rane, Jitendra Subhash [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.26434/chemrxiv.12198369 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XCH017750989 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XCH017750989 | ||
| 003 | DE-627 | ||
| 005 | 20230429143348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200429s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26434/chemrxiv.12198369 |2 doi | |
| 035 | |a (DE-627)XCH017750989 | ||
| 035 | |a (chemrXiv)10.26434/chemrxiv.12198369 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rane, Jitendra Subhash |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting Virus-Host Interaction: An in Silico Approach to Develop Promising Inhibitors Against COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The entire human population all over the globe is currently facing appalling conditions due tothe spread of infection from COVID-19 (corona virus disease-2019). In the last few monthsenormous amount of studies have been continuously trying to target several potential drugsites to identify a novel therapeutic target. Spike protein of severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2) is also being targeted by several scientific groups as a noveldrug target. The spike glycoprotein protein is present on the surface of the virion and binds tothe human angiotensin-converting enzyme-2 (hACE2) membrane receptor thereby promotingits fusion to the host cell membrane. The binding and internalization of the virus is a crucialstep in the process of infection and hence any molecule that can inhibit this, certainly holds asignificant therapeutic value. We have identified AP-NP (2-(2-amino-5-(naphthalen-2-yl)pyrimidin-4-yl)phenol) and AP-4-Me-Ph (2-(2-amino-5-(p-tolyl)pyrimidin-4-yl)phenol)from a group of diaryl pyrimidine derivatives which appear to bind at the interface ofhACE2-SARS-CoV-2S complex (human angiotensin converting enzyme 2 and spikeglycoprotein complex) with a low binding energy (<-8 Kcal/mol). In this in-silico study wealso found that AP-NP interacts with S1 domain of C-terminal part of SARS-CoV-2Showever AP-4-Me-Ph was found to interact with S2 domain of SARS-CoV-2S. The resultsuggested that AP-NP and AP-4-Me-Ph have potential to inhibit the interaction betweenspike protein and hACE2 receptor also AP-4-Me-Ph might be prevent internalization of thevirion within the host. Further in vitro and in vivo study will strengthen these drug candidatesagainst the COVID-19. | ||
| 650 | 4 | |a Chemistry |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 540 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Chatterjee, Aroni |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Rajni |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Abhijeet |e verfasserin |4 aut | |
| 700 | 1 | |a Ray, Shashikant |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t chemRxiv.org |g (2021) vom: 18. Nov. |
| 773 | 1 | 8 | |g year:2021 |g day:18 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26434/chemrxiv.12198369 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XCH | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 18 |c 11 | ||